SOURCE: IsoRay, Inc.

IsoRay, Inc.

October 21, 2013 09:15 ET

Johns Hopkins and Rutgers Medical School Now Utilizing IsoRay's Cesium-131 Sutured Seeds in Treating Metastatic Brain Cancer

Isoray's Cesium-131 Neurosurgical Solutions Continue to Gain Acceptance and Are on Display at the Annual Meeting of the Congress Of Neurological Surgeons (CNS)

RICHLAND, WA--(Marketwired - Oct 21, 2013) -  IsoRay Inc. (NYSE MKT: ISR) (NYSE Amex: ISR) (, a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it will host a booth October 21-24th at the Annual Meeting of the Congress of Neurological Surgeons. These meetings provide a major forum for IsoRay to demonstrate its products, educate attendees and present the successes being experienced by major medical centers utilizing IsoRay's products as they fight difficult cancers throughout the body. 

IsoRay CEO Dwight Babcock noted, "We are extremely encouraged by the number of posters, abstracts and oral presentations being presented at various meetings in 2013, reporting the positive results being realized in treating various brain cancers, meningioma tumors, lung cancer, gynecologic cancer and prostate cancer with our Cesium-131 products. Medical thought leaders recognize the need for a new powerful weapon in the battle against cancer and we believe Cesium-131 is that answer. Our solutions are now providing hope for those suffering from these horrible diseases."

IsoRay's neurosurgical applications utilizing Cesium-131 sutured seeds, stranded mesh and the GliaSite® radiation therapy system each give physicians the ability to directly place a specified dosage of radiation in areas where cancer is most likely to remain after completion of brain tumor removal. The ability to precisely place a specified dose of radiation means there is less likelihood for damage to occur to healthy brain tissue as well as critical structures compared to other alternative treatments. IsoRay's cancer fighting products reduce the ability of the tumor to recur, which means important benefits for patients in longevity as well as quality of life.

IsoRay is the exclusive manufacturer of Cesium-131. Cesium-131 is the first new isotope to be available in seed form for brachytherapy in approximately 20 years. Cesium-131 allows for the precise treatment of many different cancers because of its unrivaled blend of high energy and its 9.7 day half-life (its unequaled speed in giving off therapeutic radiation).

In addition to its CMS codes, Cesium-131 is FDA-cleared and holds a CE mark for international sales in seed form for the treatment of brain cancer, prostate cancer, lung cancer, ocular melanoma cancer, colorectal cancer, gynecologic cancer, head and neck cancer and other cancers throughout the body. The treatment can be deployed using several delivery methods including single seed applicators, implantable strands and seed sutured mesh, and several new implantable devices. IsoRay also distributes the GliaSite® radiation therapy system, used to treat brain cancers. 

About IsoRay
 IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of GliaSite® and Cesium-131 by visiting Join us on Facebook/IsoRay. Follow us on Twitter@isoray.

Safe Harbor Statement
Statements in this news release about IsoRay's future expectations, including: the advantages of our Cesium-131 seed and its various delivery formats, the advantages of the Gliasite® delivery system, whether IsoRay will be able to continue to expand its base beyond prostate cancer, whether the use of GliaSite® or Cesium-131 will increase or continue, whether future studies of treatment of various cancers using our products will have favorable results, whether presentations at industry meetings will continue to be made in the future, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether additional studies are released and support the conclusions of past studies, patient results achieved with Cesium-131 or the Gliasite® delivery system, successful completion of future research and development activities, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use Cesium-131 in its various forms as well as our other products in the U.S. and internationally, continued compliance with ISO standards as audited by BSI, and other risks detailed from time to time in IsoRay's reports filed with the SEC.

Contact Information